Close menu




July 12th, 2022 | 14:09 CEST

Waiting is not an option! BioNTech, MAS Gold, BASF

  • Gold
  • Biotechnology
  • Inflation
Photo credits: pixabay.com

Inflation is rising and rising. In construction, inflation has already reached almost 20%. Even in everyday life, double-digit inflation rates are not far away. At the same time, infection figures are rising, and it is still uncertain whether gas will flow through Nord Stream 1 again in the coming weeks. Given this mixed situation, many investors are asking how they should invest. Because one thing is clear: waiting is not an option - the real return on many asset classes is clearly negative. We take a look at three stocks and check their future prospects.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , MAS Gold Corp. | CA57457A1057 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    BioNTech: Well prepared for the fall

    Whether BioNTech can emerge as the winner of the Corona situation is not yet certain. Since BioNTech has two hot candidates for the upcoming Corona season, the Company is well-positioned. Actually. Experts from the US Food and Drug Administration (FDA), among others, are currently discussing which vaccines should be launched on the market in the fall. The manufacturers offer solutions specifically directed against Omicron or products intended to be effective against both the original type and Omicron. Doses of the first batches of the vaccines are also still in stock. Given the number of possible solutions, experts warn that the logistics surrounding the vaccines could become more complex, and BioNTech's margins could suffer.

    Nevertheless, the chances are good that the vaccine professionals from Mainz will be able to offer exactly what experts are demanding and vaccinators are accepting in the fall. Since the pandemic has shown that a lot can happen and little can be planned, BioNTech could be well-positioned. The stock also looks attractive from a chart perspective. The share is currently fighting its way out of the sideways movement that has lasted since February. However, it remains to be seen whether the breakout will be successful - BioNTech is now an established stock, making big jumps less likely.

    MAS Gold: Is history repeating itself?

    MAS Gold is the opposite of an established value - at least in Europe. The Company is exploring the La Ronge gold belt in Canada's Saskatchewan province. MAS Gold has several promising smaller properties and is developing them in parallel. The plan is to implement a hub-and-spoke model, where a central processing plant reduces costs and creates flexibility. But for these goals to be achieved, the gold in the ground is critical. A few weeks ago, MAS Gold announced drill results from one-third of its winter drill program. Grades ranging from 0.49 g/t to 3.06 g/t came to light. The task of the Company, led by mining legend Jim Engdahl, will now be to further delineate the deposits and get a picture of the high-grade zones.

    MAS Gold's own belief in moving its projects forward is also evidenced by a financing round involving management and company insiders. With the overall market weakening, especially on the financing side, the stock has come under significant pressure despite the recent successful closing of the capital tranche. This "cliffhanger" can be an opportunity for courageous investors: If MAS Gold successfully implements its strategy and the gold market picks up speed in the wake of general uncertainty, current price levels could be promising. The development of inflation and gold during the 1970s could provide guidance. At that time, gold also only got going with a time lag!

    BASF: More fear than hope

    And what about industrial companies? During past crises, investors could always be sure: In the long term, stocks like BASF always get back on track. And today? Today, energy-intensive industries such as chemicals are threatened with collapse. BASF is painstakingly giving itself a sustainable profile, but tens of thousands of precursors from the Ludwigshafen plant still depend on fossil fuels. If contrary to plans, no more gas flows through Nord Stream 1 in two weeks, shares like BASF will likely come under renewed pressure. The Ludwigshafen shares have already fallen by around 16% in the last three months.


    Inflationary pressure and crisis fears are a dangerous mix. One thing is certain: those investors who do nothing will have to accept a loss of purchasing power in any case, and those who invest incorrectly, likewise. One approach could be to focus on companies that suffer little from the energy price shock and may even have a low valuation. One such candidate, albeit a highly speculative one, is MAS Gold. BioNTech also looks interesting at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Nico Popp on January 14th, 2026 | 07:20 CET

    Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer

    The investment year 2026 marks a decisive turning point for the global biotechnology and pharmaceutical sector. After a period of macroeconomic uncertainty, we are witnessing a renaissance in the life sciences, driven by two fundamental forces: the urgent need for big pharma players to replace their expiring patents with innovation, and the scientific breakthrough of novel mechanisms of action in agile biotech small caps. While industry giants such as Pfizer and Bayer are attempting to steer their cumbersome tankers onto a new course through massive restructuring, the as-yet little-noticed biotech company Vidac Pharma is delivering the technological innovation the market is looking for. With an approach that directly addresses cancer metabolism and reverses the "Warburg effect," which has been known for almost a century, Vidac is positioning itself as a disruptive force in oncology and dermatology. For investors, this constellation offers a rare opportunity: to observe the stability of the giants while betting on the explosive potential of a technological innovator that analysts say is massively undervalued.

    Read

    Commented by André Will-Laudien on January 13th, 2026 | 07:40 CET

    Silver +200% - Gold doubles! Time for acquisitions? Barrick, B2Gold, Desert Gold, Glencore, and Rio Tinto in focus!

    • Mining
    • Gold
    • Silver
    • Commodities
    • Investments

    The geopolitical situation brings new uncertainties every day. Most recently, markets reacted strongly to news around the removal of Venezuelan President Maduro, and now massive unrest in Iran has been added to the mix! Commodity prices are galloping against the backdrop of fragile supply chains and the formation of Eastern and Western power blocs with conflicting interests. While the US is formulating its expansionist agenda towards Greenland and Canada, China is responding with further export restrictions. This is exacerbating the situation even further and driving up the prices of silver to USD 85 and gold to over USD 4,600. Both established mines and promising projects are coming into focus, and takeover rumors are circulating once again. How are investors supposed to keep track of all this? We are happy to help.

    Read

    Commented by Armin Schulz on January 13th, 2026 | 07:15 CET

    Gold boom in 2026: Be on the right side with Newmont, Kobo Resources, and B2Gold

    • Mining
    • Gold
    • Commodities
    • geopolitics
    • Investments

    Gold is experiencing an unprecedented surge, driven by geopolitical turmoil, a sustained run on gold by central banks, and eroding confidence in fiat currencies. This perfect constellation has pushed the price to record levels and is creating an exceptional environment for select mining companies. Mining giant Newmont, exploration specialist Kobo Resources, and growth producer B2Gold are in focus.

    Read